Activation of tissue angiotensin II (Ang II) type 1 receptor (AT1R) plays an important role in the development of vascular remodelling. We have shown that the AT1R-associated protein (ATRAP/Agtrap), a specific binding protein of AT1R, functions as an endogenous inhibitor to prevent pathological activation of the tissue renin-angiotensin system. In this study, we investigated the effects of ATRAP on Ang II-induced vascular remodelling.
Introduction
Vascular hypertrophy is a hallmark feature of the end-organ damage from hypertension that contributes actively to clinical morbidity and mortality. 1 The renin -angiotensin system (RAS) is a major determinant of both physiological and pathological vascular function. Angiotensin II (Ang II), the most potent RAS component, induces vasoconstriction in a variety of tissues, mainly through its binding to the Ang II type 1 receptor (AT1R) in vascular smooth muscle cells (VSMCs). The long-term stimulation of vascular AT1R leads to cell proliferation, inflammation, hypertrophy, and fibrosis. 2 In addition, accumulating evidence shows that the activation of AT1R at local tissue sites plays an important role in the development of vascular remodelling. The carboxyl-terminal portion of AT1R is involved in the control of AT1R internalization independent of G-protein coupling, and it plays a key role in linking receptor-mediated signal transduction to the specific biological responses to pathological stimuli such as Ang II. The AT1R-associated protein (ATRAP/Agtrap) was identified as a molecule that directly binds to the carboxyl-terminal domain of AT1R in the course of an investigational search for a means to regulate AT1R signalling at local tissue sites. 5 -8 Our previous studies showed that ATRAP selectively suppresses Ang II-mediated pathological responses in cardiovascular cells, and also ameliorates cardiac hypertrophy and renal angiotensinogen production in chronic Ang II-infused mice. 9 -13 However, little is known about the role of ATRAP in Ang II-mediated vascular hypertrophy in vivo. NADPH oxidase-derived reactive oxygen species (ROS) function as important intracellular second messengers to activate many downstream signalling molecules, such as tyrosine phosphatases, tyrosine kinases, mitogen-activated protein kinase (MAPK), and transcriptional factors. 14 -17 Activation of these signalling cascades leads to VSMC growth and migration, modulation of endothelial function, expression of pro-inflammatory mediators, and modification of extracellular matrix. All these processes play important roles in hypertension-associated vascular remodelling. The classical NADPH oxidase is a multimeric enzyme that originally was described in neutrophils, while the phagocytic NADPH oxidase consists of five subunits. 18, 19 Gp91 phox (renamed Nox2) and p22 phox comprise the cytochrome b558 membrane complex, which is localized in submembranous vesicles and the plasma membrane. p47 phox , p67 phox , and the small molecular weight G-protein Rac are cytosolically localized and do not interact with the cytochrome in resting cells. A new family of homologous catalytic subunits referred to as Nox1-5 were more recently discovered and give their corresponding oxidase systems their names. 20, 21 Nox1, Nox2, and Nox4 reportedly require the other membrane component p22 phox for stabilization and to form functional ROS-generating NADPH oxidase enzymes. With respect to the relationship between these NADPH oxidases and vascular hypertrophy, previous reports using genetically modified animals showed that the overexpression of Nox1 or p22 phox enhanced pathological vascular hypertrophy, while knockout of Nox1 or Nox2 attenuated it. 22 -25 On the other hand, several studies also showed that activation of AT1R signalling through tissue RAS stimulates multiple molecular targets in an ROS-dependent manner. 26 -28 However, the functional effects of ATRAP on the activation of vascular NADPH oxidase via AT1R signalling in response to Ang II have yet to be elucidated. The present study was designed to obtain in vivo evidence of the vascular function of ATRAP, and focused on its modulatory effects on the Ang II-mediated vascular responses including oxidative stress and signalling, the key pathways linked to the AT1R activation that is involved in the development of pathological vascular remodelling.
Methods
Mice were housed under a 12 h day-night cycle at a temperature of 258C. Mice were anaesthetized by intraperitoneal injection of pentobarbital (50 mg/kg body weight), and the adequacy of anaesthesia was evaluated by monitoring toe-pinch reflex and regular respiration. The protocol was reviewed and approved by the Animal Studies Committee of Yokohama City University, and all experiments were performed in accordance with the National Institutes of Health guidelines for the use of experimental animals.
Generation of ATRAP transgenic (Tg) mice
We generated ATRAP Tg mice on a C57BL/6 background as described previously. 11 Briefly, haemagglutinin (HA)-tagged mouse ATRAP cDNA was subcloned into a pCAGGS expression vector, which contains a cytomegalovirus enhancer and the chicken b-actin promoter, as illustrated in Figure 1A .
The resultant transgene construct was microinjected into the pronuclei of fertilized mouse embryos. The ATRAP transgene-positive mice were mated with C57BL/6 wild-type (Wt) mice to obtain ATRAP transgenepositive mice and littermate control mice for the experiments. Tg mice were identified by polymerase chain reaction (PCR), using forward (TGCTTGGGGCAACTTCACTATC) and reverse (ACGGTGCATGTG GTAGACGAG) primers. PCR was performed as follows: 958C for 30 s, 608C for 30 s, and 728C for 1 min for a total of 35 cycles, with a final extension step at 728C for 10 min.
Chronic Ang II stimulation procedures
Ang II (500 ng/kg/min) or vehicle was continuously infused into male mice aged 10 -12 weeks subcutaneously via an osmotic minipump (model 2002; Alzet) for 14 days as described previously.
11,12,29 Total RNA was extracted from the tissues with ISOGEN (Nippon Gene), and the cDNA was synthesized using the SuperScript III First-Strand System (Invitrogen). For total RNA extraction from the aortas, the aortic tissues were carefully isolated from mice and immediately immersed in RNA later solution (Life technologies). Fat and connective tissues in the adventitia were then removed from the aortic tissue under a binocular microscope. Endothelium was removed by gently rubbing the intima with a cotton swab to avoid the endothelium-dependent effect. Real-time qRT-PCR was performed by incubating the reverse transcript product with TaqMan Universal PCR Master Mix and a designed TaqMan probe (Applied Biosystems), essentially as described previously. 31, 32 RNA quantity was expressed relative to the 18S rRNA endogenous control.
Histological analysis
Aortas from mice were fixed with 4% paraformaldehyde and subsequently embedded in paraffin. The sections of 4-mm thickness were stained with haematoxlin/eosin, elastica van gieson, and an immunohistochemical antibody. The aortic medial thickness and renal afferent arteriolar wall thickness were measured digitally using the Image Proplus software, as described previously. 31 Twenty afferent arteriolar walls were examined for each mouse, and the averaged thickness of the wall of afferent arterioles was determined for each mouse. Immunohistochemistry was performed essentially as reported previously. 11, 31, 33 Briefly, the sections were dewaxed and rehydrated, and antigen retrieval was performed by microwave heating. The sections were blocked for endogenous biotin activity using peroxidase blocking reagent (DAKO) and treated for 60 min with 10% normal goat serum in phosphate-buffered saline. The sections were then incubated with anti-ATRAP antibody diluted to 1:100 and 4-hydroxy-2-noneal (4-HNE) antibody diluted to 1:100 (Japan Institute for the Control of Aging).
Determination of MAPK family activity
Western blot analysis was performed for activated MAPK family; phosphorylated p38MAPK, extracellular signal-regulated protein kinase 1/2 (ERK), and c-Jun N-terminal kinase (JNK) using anti-phospho-p38MAPK antibody (V1211, Promega), anti-phospho-ERK antibody (#4370, Cell Signaling Technology), and anti-phospho-JNK antibody (#4668, Cell Signaling Technology), which recognize only activated p38MAPK, ERK1/2, and JNK, respectively, as described previously. 16 The total protein extracts were prepared from the aortas, with the same procedure for the removal of endothelium and adventitia as in the case for total RNA extraction from aorta, with SDS-containing sample buffer. The protein concentration of each sample was measured with a DC protein assay kit (Bio-Rad) using bovine serum albumin as the standard. Equal amounts of protein extract from the tissue samples were fractionated on a 5 -20% polyacrylamide gel (ATTO), then transferred to a polyvinylidene difluoride (PVDF) membrane using the iBlot Dry Blotting System (Invitrogen). Membranes were blocked for 1 h at room temperature with phosphate-buffered saline containing 5% skim milk powder, and probed overnight at 48C with specific primary antibodies. To detect total p38MAPK, ERK, and JNK, anti-p38MAPK antibody (sc-728, Santa Cruz Biotechnology), anti-ERK antibody (#4695, Cell Signaling Technology), and anti-JNK antibody (sc-571, Santa Cruz Biotechnology) were used.
Cultured VSMC analysis
VSMCs were aseptically isolated from thoracic aortic explants of 5-week-old Sprague -Dawley rats, as described previously. 10, 34 Cells were grown on 100-mm dishes (Corning) in DMEM/HAM F-12 media (1:1, Sigma-Aldrich) supplemented with 5% heat-inactivated foetal calf serum (MBL), 2 mM L-glutamine (GIBCO), 0.5 mg/mL streptomycin, 0.5 mg/mL penicillin, and 1 mg/mL neomycin (GIBCO) in a humidified atmosphere of 5% CO 2 -95% air. Adenoviral vectors were prepared using cDNAs coding for the aminoterminal HA epitope-tagged ATRAP (Ad.HA-ATRAP) and bacterial b-galactosidase (Ad.LacZ) using a commercially available system (Adeno X Expression System, Clontech), and the virus titre was determined with a plaque assay. 9, 10 For the adenoviral gene transfer experiments, VSMCs were subcultured in 6-cm diameter dishes (5 × 10 4 /mL), incubated overnight, infected with recombinant adenovirus (Ad.HA-ATRAP or Ad.LacZ) at 50 multiplicity of infection for 24 h and then further incubated in a serumfree medium for an additional 24 h. The cells were then treated with Ang II (10 27 M) for the indicated time and subsequently harvested for analysis, as described previously.
9,10,35
Statistical analysis
Statistical analysis was performed using GraphPad Prism software. All of the quantitative data are expressed as means + SE. Differences were analysed by Student's unpaired t-test or analysis of variance (ANOVA) followed by the Newman -Keuls multiple comparison test. Values of P , 0.05 were considered statistically significant.
Results

Generation of aortic vascular-dominant ATRAP Tg mice
To investigate a functional role of vascular ATRAP in vivo, we generated Tg mice with a pattern of vascular-dominant overexpression of ATRAP, and compared them with Wt littermates mice ( Figure 1B) . The aortic ATRAP mRNA expression in Tg mice was 10-fold higher than Wt mice, and the cardiac ATRAP mRNA expression in Tg mice was also higher than Wt mice by 5-fold. On the other hand, less efficient ATRAP expression was observed in the other tissues analysed ( Figure 1B) . Intriguingly, the results of immunohistochemical analysis using the anti-ATRAP antibody revealed that the ATRAP transgene was potently expressed in the medial area of thoracic aorta, but not in the renal afferent arterioles, in the Tg mice ( Figure 1C and D) .
Since the degree of ATRAP overexpression in the aorta of Tg mice is rather high, we next examined whether aortic vascular ATRAP overexpression would exert an influence on the expression of other G-coupled receptor proteins, such as endothelin type A (ETA) receptor and alpha 1-adrenergic receptor, in the aorta of Tg mice. However, as shown in Supplementary material online, Figure S1 , the mRNA expression levels of ETA receptor and alpha 1-adrenergic receptor in the aorta of Tg mice were comparable with those in the aorta of Wt mice.
Effects of chronic Ang II infusion on BP in mice
To examine the effects of aortic vascular ATRAP enhancement on Ang II-mediated hypertension, we compared BP between the Wt and Tg Figure S2 ). To strictly compare the effects of Ang II infusion on BP between the Wt and Tg mice, we performed direct BP measurement by radiotelemetric device. The SBP of the Tg mice was comparable with that of Wt mice at baseline and during the Ang II infusion (two-way repeated-measures ANOVA F ¼ 0.2924, P ¼ 0.6054) (Figure 2A) . The SBP increase in response to Ang II infusion was also comparable in the Wt and Tg mice ( Figure 2B , unpaired t-test, P ¼ 0.8979). Regarding other parameters obtained by radiotelemetry, diastolic BP (DBP), mean arterial pressure (MAP), and heart rate (HR) of the Tg mice were also similar to those of Wt mice during the Ang II infusion ( Figure 2C-F) . These results indicated that aortic vascular-dominant overexpression of ATRAP did not affect BP in response to chronic Ang II infusion.
Effects of chronic Ang II infusion on aortic vascular hypertrophy in mice
Since activation of AT1R signalling though the tissue RAS is involved in the pathogenesis of vascular injury and remodelling, we next examined whether aortic vascular-dominant overexpression of ATRAP would attenuate aortic vascular remodelling provoked by chronic Ang II infusion. As shown in Figure 3 , there was no difference in the histological vascular morphology at baseline in the thoracic and abdominal aortas between the Wt and Tg mice, which is consistent with there having been no apparent phenotypic changes observed under physiological conditions at baseline in other ATRAP transgenic mice. 11, 12 However, the development of aortic vascular hypertrophy provoked by Ang II infusion was partially inhibited in the thoracic and abdominal aortas of the Tg mice ( Figure 3A and B) . On the other hand, in afferent arterioles of the kidney which are resistance vessels, Ang II infusion for 2 weeks significantly increased vascular wall thickness in the Wt and Tg mice to the similar extent ( Figure 3C ).
Effects of chronic Ang II infusion on cardiac hypertrophy in mice
Overexpression of ATRAP was observed in the heart in addition to the aorta in Tg mice in the present study and the cardiac expression level of ATRAP transgene was 50% of the aortic ATRAP expression level ( Figure 1B) . Based on these observations, we next examined whether the Ang II-mediated cardiac hypertrophy was affected in the Tg mice. While Ang II infusion for 2 weeks significantly increased the heart weight/body weight ratio in the Wt mice (4.07 + 0.17 vs. 4.72 + 0.13 mg/g, P , 0.05), the Ang II-mediated increase in the heart weight/ body weight ratio was inhibited in the Tg mice (4.02 + 0.13 vs. 4.12 + 0.16 mg/g, NS) (Supplementary material online, Figure S3 ). These findings are consistent with the previous results in other ATRAP Tg mice with cardiomyocyte-specific overexpression of ATRAP. 16 
Effects of chronic Ang II infusion on aortic vascular NADPH oxidase and ROS in mice
To investigate a mechanism involved in the partial inhibition of aortic vascular remodelling in response to Ang II in the ATRAP Tg mice, we examined aortic NADPH oxidase expression and ROS production. We compared the mRNA expression of the NADPH oxidase components (NOX1, NOX2, NOX4, p22 phox , p47 phox , and Rac1) in the aorta of the Wt and Tg mice. Ang II infusion for 2 weeks significantly increased the aortic vascular mRNA expression levels of p47 phox and NOX1 in both mice ( Figure 4A-D) , and the vascular Rac1 and Nox2 mRNA levels also tended to increase in response to Ang II infusion in both types of mice to the similar extent ( Figure 4B and C ) . However, the Ang II-mediated enhancement of aortic vascular Nox4 and p22 phox mRNA expression was dramatically suppressed in the Tg mice ( Figure 4E and F ) . These results indicated that the Ang II-mediated activation of several different NADPH oxidase components was inhibited in the Tg mice. Since the NADPH oxidase components produce ROS, the suppression of their expression may have resulted in a reduction in aortic vascular ROS generation in the Tg mice. To evaluate the changes in vascular ROS status in the Wt and Tg mice, we examined the aortic immunostaining of 4-HNE, which reflects the tissue ROS generation. 36 -38 In Tg mice, the Ang II-mediated increase in the aortic 4-HNE immunostaining was apparently suppressed compared with Wt mice (Figure 4G ).
Effects of chronic Ang II infusion on aortic vascular MAPK activation in mice
As the downstream signalling pathway of the AT1R, we compared the activation of MAPK family in the aorta of Wt and Tg mice during Ang II stimulation. As shown in Figure 5A , vascular ERK was significantly activated by Ang II infusion in both types of mice to a similar extent. On the other hand, JNK activation by Ang II infusion was partially inhibited in the aorta of Tg mice when compared with Wt mice ( Figure 5B ). Furthermore, Ang II-mediated activation of aortic vascular p38MAPK was almost abolished in the Tg mice ( Figure 5C ).
Effects of Ang II infusion on NADPH oxidase in VSMCs
As described above, the aortic ATRAP enhancement attenuated the Ang II-mediated vascular hypertrophy, with a concomitant suppression of NADPH oxidase expression, ROS generation, and MAPK activation in vivo. However, the Tg mice produced in the present study are an aortic vascular-dominant, but not a VSMC-specific model. Therefore, to analyse the direct effect of ATRAP on Ang II-mediated regulation of NADPH oxidase, we examined whether overexpression of ATRAP would suppress the Ang II-mediated NAPDH oxidase expression in 
Discussion
In the present study, we showed that ATRAP significantly but not completely inhibits the expression of aortic vascular NADPH oxidase, ROS generation, and MAPK activation in response to chronic Ang II infusion in vivo, with a partial inhibition of the development of aortic vascular hypertrophy, but without affecting Ang II-induced BP elevation. These partial protective effects of aortic vascular ATRAP in vivo are also supported by in vitro experimental data in VSMCs using adenoviral transfer of recombinant ATRAP. In VSMCs, Ang II-mediated activation of the AT1R signalling induces potent vasoconstriction. Since ATRAP is a functional inhibitor of pathological activation of AT1R signalling, one would expect that aortic vascular-dominant ATRAP Tg mice would exhibit anti-hypertensive property against Ang II-mediated hypertension through the suppression of vasoconstriction. However, interestingly, the hypertensive response to chronic Ang II infusion was not affected in the aortic vasculardominant ATRAP Tg mice. In other words, tissue ATRAP enhancement in the large arteries is not sufficient to inhibit the Ang II-mediated BP elevation. Alternatively, the inhibition of Ang II-induced hypertension may require tissue ATRAP activation in smaller resistant arteries, central nervous system, or kidney. In the present study, no substantial enhancement of ATRAP expression was observed in the brain and kidney, including afferent arterioles of Tg mice compared with Wt mice, supporting this possibility. In this regard, previous studies showed that VSMC-specific AT1R deletion in mice did not affect the hypertensive response to chronic Ang II infusion, while the Ang II-induced hypertension was significantly inhibited in mice specifically lacking renal AT1R. 39, 40 With respect to tissue oxidative stress modulation, there are two different phases of ROS generation. One is rapid and transient, and the other is delayed and sustained. In VSMCs, rapid ROS release requires p47 phox via its phosphorylation by protein kinase C (PKC) and subsequent translocation to the membrane. 41, 42 On the other hand, the sustained phase of ROS generation is preceded by up-regulation of Nox1 and Nox4. 43, 44 Nox1 and Nox4 directly interact with p22 phox and stabilize the enzyme structure to maintain stimulated ROS generation. 45 Importantly, the aortic vascular-dominant ATRAP Tg mice exhibited a significant suppression of the Ang II-mediated activation of aortic vascular Nox4 and p22 phox expression compared with the Wt mice, thereby suggesting that the sustained phase of aortic vascular ROS generation under stimulation is inhibited in the Tg mice.
In the present study, the inhibition of Ang II-mediated elevation of aortic vascular Nox4 and p22
phox was accompanied by suppression of Ang II-induced activation of aortic vascular 4-HNE, an established marker of tissue ROS generation, 36 -38 in the Tg mice. In addition, the Ang II-mediated activation of aortic vascular p38MAPK and JNK was also inhibited in the Tg mice. The ROS-p38MAPK/JNK-dependent signalling cascade is reported to be involved vascular pathophysiology and, in particular, p38MAPK is a critical component of the oxidative stress-sensitive signalling pathways activated by Ang II in VSMC as a critical player in vascular hypertrophy. 46, 47 On the other hand, the activation of aortic ERK was not blocked in the aortic vascular-dominant ATRAP Tg mice under chronic Ang II infusion, and this finding would not be consistent with the results of previous studies showing inhibitory effects of ATRAP on the ERK activation by Ang II stimulation in VSMCs and by cuff-mediated inflammatory vascular injury in mice. 48, 49 This discrepancy regarding the inhibitory effect of ATRAP on vascular ERK activation may be derived from the differences in experimental models analysed (i.e. in aortic vascular-dominant ATRAP Tg mice vs. in ATRAP-plasmid transfected VSMCs and chronic Ang II infusion vs. cuff-mediated vascular injury). Therefore, further studies are necessary to determine how ATRAP functions and possible novel mechanisms of vascular ATRAP action, including pleiotropic effects on ERK activity. 8 Collectively, the ATRAP enhancement-mediated inhibitory effects on aortic vascular Nox4/p22 phox -ROS-p38MAPK/JNK pathway is suggested to contribute to the partial inhibition of aortic vascular hypertrophy in response to Ang II-mediated hypertension in the Tg mice.
Since we employed the chicken b-actin promoter, but not more conventional promoters like SMHC kinase or SM22alpha, for aortic vascular ATRAP expression, the results do not allow us to completely distinguish the aortic vascular ATRAP functions, a limitation of the present study. The Tg mice with aortic vascular-dominant overexpression of ATRAP were unexpectedly and fortuitously obtained upon a screening for cellular expression in these transgenic animals. Strictly this model is not a specifically targeted cellular overexpression model, but rather, a model in which there is variation in ATRAP expression in the tissues. While the aortic vascular wall is a predominant ATRAP expression site, other tissues do overexpress ATRAP to some degree in Tg mice. In addition, the ATRAP overexpression only limited, but did not completely suppress, the Ang II-mediated vascular trophic effects in this study. Thus, probably the residual vascular hypertrophy by Ang II could be due to a direct effect of mechanical stress/strain by BP increase but not mediated by Ang II itself. Therefore, it is necessary to further investigate the role of VSMC ATRAP in angiotensin-mediated vascular pathophysiology in vivo using cellular-targeted models and in mechanical stress-mediated vascular complication in vivo using pressure-overload models.
In summary, the present study showed that aortic vascular ATRAP enhancement is able to partially inhibit the hypertension-associated pathological aortic vascular hypertrophy with a concomitant inhibition of NADPH oxidase, ROS production and MAPK activity, but without apparent effect on the development of hypertension, under chronic Ang Angiotensin receptor-binding protein and vascular hypertrophy II stimulation in mice. These results suggest ATRAP as a possible candidate for a novel therapeutic target in vascular injury and pathological remodelling. However, since the results obtained in this study are essentially derived from the experiments using transgenic mice, it is important to exercise caution in interpreting the finding to be relevant to the pathophysiology of human vascular disease. Nevertheless, identification of ATRAP as a novel receptor-binding modulator of vascular pathophysiology not only has cardiovascular significance but may also have generalized implication in the regulation of tissue function.
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